AstraZeneca says preliminary data from a trial shows that its COVID-19 vaccine, Vaxzevria, generated an increase in antibodies against Omicron and other variants when given as a third booster dose. AstraZeneca country president Lotis Ramin joins us.<br /><br /><br />Visit our website for more #NewsYouCanTrust: https://www.cnnphilippines.com/<br /><br />Follow our social media pages:<br /><br />• Facebook: https://www.facebook.com/CNNPhilippines<br />• Instagram: https://www.instagram.com/cnnphilippines/<br />• Twitter: https://twitter.com/cnnphilippines<br />
